A 58-year-old man with a 10-year history of Type 2 diabetes presents for routine follow-up. His HbA₁c is 8.2%, fasting glucose 156 mg/dL, and eGFR 62 mL/min/1.73m². He has hypertension and mild albuminuria. He is currently on metformin monotherapy. Which agent should be added as second-line therapy to provide cardio-renal protection?

Explanation

## Type 2 Diabetes: Second-Line Therapy with Cardio-Renal Benefits **Key Point:** In Type 2 diabetes patients with chronic kidney disease (CKD) and/or albuminuria, second-line agents should provide both glycemic control AND cardio-renal protection, not just glucose lowering. ## SGLT2 Inhibitors: The Evidence ### Mechanism of Empagliflozin 1. Inhibits sodium-glucose cotransporter 2 in the proximal tubule 2. Increases urinary glucose excretion (glycosuria) 3. Reduces intraglomerular pressure and protects the glomerular filtration barrier 4. Reduces sympathetic tone and improves cardiac afterload ### Cardio-Renal Benefits (EMPA-REG OUTCOME, EMPA-KIDNEY trials) | Benefit | Evidence | |---|---| | **Albuminuria reduction** | 30–40% reduction in urine albumin-to-creatinine ratio | | **CKD progression slowing** | Slows eGFR decline; delays need for dialysis/transplant | | **Cardiovascular mortality** | 25% reduction in CV death (EMPA-REG) | | **Heart failure hospitalization** | 35% reduction in HF hospitalizations | | **Hypoglycemia risk** | Minimal (insulin-independent mechanism) | **High-Yield:** SGLT2 inhibitors (empagliflozin, dapagliflozin) are now **first-line add-on to metformin** in Type 2 diabetes with CKD or albuminuria, regardless of baseline HbA₁c. This patient has both—making empagliflozin the ideal choice. **Clinical Pearl:** Unlike sulfonylureas and thiazolidinediones, SGLT2 inhibitors do NOT cause weight gain and actually promote modest weight loss (1–3 kg), an additional benefit in this obese population. **Mnemonic:** **SGLT2i = Slow Glomerular Loss, Tubular reabsorption Inhibited** — they protect the kidney by reducing intraglomerular hyperfiltration. ## Why Other Drugs Are Suboptimal ### Glibenclamide (Sulfonylurea) - Increases insulin secretion but offers no renal protection - Risk of hypoglycemia and weight gain - Associated with increased cardiovascular events in some trials - Contraindicated in CKD due to hypoglycemia risk ### Acarbose (α-Glucosidase Inhibitor) - Slows carbohydrate absorption; modest glycemic benefit only - No cardio-renal protection - Causes GI side effects (bloating, diarrhea) - Not recommended as second-line in this scenario ### Pioglitazone (Thiazolidinedione) - Improves insulin sensitivity and has some renal protective data - However, causes weight gain (2–4 kg) and fluid retention - Risk of heart failure exacerbation - Less preferred than SGLT2i in modern practice for CKD ## Current Guidelines **American Diabetes Association (2023):** In Type 2 diabetes with CKD (eGFR 30–90) or albuminuria, add an SGLT2 inhibitor or GLP-1 receptor agonist to metformin for cardio-renal protection, independent of HbA₁c target. [cite:Harrison 21e Ch 417; ADA Standards of Care 2023]